June 1, 2021
Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a worldwide immunology firm dedicated to bettering the lives of individuals affected by extreme autoimmune illnesses and most cancers, at this time introduced the appointment of Mr. Karl Gubitz as Chief Monetary Officer. Mr. Gubitz brings to argenx practically 20 years of world pharmaceutical management expertise, particularly in monetary planning and evaluation, enterprise partnerships and product commercialization. He’ll succeed Eric Castaldi, who will stay with the corporate by June 30, 2021.
“We’re delighted to welcome Karl to our govt management crew as he has a formidable observe document of efficiently establishing industrial organizations and offering strategic monetary path for world biopharmaceutical corporations,” stated Tim Van Hauwermeiren, CEO of argenx. “Karl’s perception and monetary experience will make him an indispensable member of the crew as we advance our imaginative and prescient of creating an built-in, modern, world immunology group that goals to impression the lives of sufferers.”
“On behalf of the argenx administration crew and Board of Administrators, we thank Eric for his important contributions as we now have grown from a personal firm to a near-commercial group. It has been a pleasure working with him and we’re grateful for the integral position he performed in our progress and success over the past seven years. He’ll at all times be part of the argenx household and we want him effectively in all his future ventures,” added Mr. Van Hauwermeiren.
Mr. Gubitz has practically 20 years of expertise as a senior finance skilled within the pharmaceutical trade at Pfizer, the place he most lately served as Vice President of Finance throughout the World Oncology enterprise. At Pfizer, he efficiently negotiated the commercialization mannequin for tanezumab with Eli Lilly in all non-U.S. markets in addition to the Myovant co-commercialization settlement for Orgovyx™. Inside Pfizer, Mr. Gubitz has held nation, regional, and world positions, and persistently delivered top-line progress. He has managed groups of over 250 colleagues in roles resembling Vice President of Finance within the World Inside Drugs enterprise and Vice President of Finance, North America within the World Revolutionary Merchandise enterprise. Previous to becoming a member of Pfizer in 2003, Mr. Gubitz held numerous administration roles at PricewaterhouseCoopers. Mr. Gubitz holds a Grasp of Enterprise Administration from Henley Administration School in the UK, a Bachelor of Computing from the College of South Africa, and a Bachelor of Commerce from the College of Pretoria.
“This can be a significantly thrilling time to be becoming a member of argenx, because the Firm nears the primary potential industrial launch of its lead product, efgartigimod,” stated Mr. Gubitz. “I sit up for working alongside this gifted crew as we transition to a commercial-stage firm and develop argenx’s world immunology footprint to enhance the lives of sufferers affected by a wide range of autoimmune illnesses.”
argenx is a worldwide immunology firm dedicated to bettering the lives of individuals affected by extreme autoimmune illnesses and most cancers. Partnering with main tutorial researchers by its Immunology Innovation Program (IIP), argenx goals to translate immunology breakthroughs right into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in a number of severe autoimmune illnesses, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx can also be advancing a number of earlier stage experimental medicines inside its therapeutic franchises. argenx has workplaces in Belgium, the USA, Japan, and Switzerland. For extra info, go to www.argenx.com and comply with us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.
For additional info, please contact:
The contents of this announcement embody statements which can be, or could also be deemed to be, “forward-looking statements.” These forward-looking statements may be recognized by way of forward-looking terminology, together with the phrases “believes,” “estimates,” “anticipates,” “expects,” “intends,” “could,” “will,” or “ought to” and embody statements argenx makes regarding its industrial readiness; its hope to achieve sufferers this yr; its statements relating to the therapeutic potential of Efgartigimod in sufferers; 2021 enterprise and monetary outlook and associated plans; the therapeutic potential of its product candidates; the meant outcomes of its technique and argenx’s, and its collaboration companions’, development of, and anticipated medical improvement, information readouts and regulatory milestones and plans, together with the timing of deliberate medical trials and anticipated information readouts; the design of future medical trials and the timing and final result of regulatory filings and regulatory approvals. By their nature, forward-looking statements contain dangers and uncertainties and readers are cautioned that any such forward-looking statements usually are not ensures of future efficiency. argenx’s precise outcomes could differ materially from these predicted by the forward-looking statements because of numerous vital elements, together with the results of the COVID-19 pandemic, argenx’s expectations relating to its the inherent uncertainties related to aggressive developments, preclinical and medical trial and product improvement actions and regulatory approval necessities; argenx’s reliance on collaborations with third events; estimating the industrial potential of argenx’s product candidates; argenx’s potential to acquire and keep safety of mental property for its applied sciences and medicines; argenx’s restricted working historical past; and argenx’s potential to acquire extra funding for operations and to finish the event and commercialization of its product candidates. An extra listing and outline of those dangers, uncertainties and different dangers may be present in argenx’s U.S. Securities and Trade Fee (SEC) filings and experiences, together with in argenx’s most up-to-date annual report on Type 20-F filed with the SEC in addition to subsequent filings and experiences filed by argenx with the SEC. Given these uncertainties, the reader is suggested to not place any undue reliance on such forward-looking statements. These forward-looking statements communicate solely as of the date of publication of this doc. argenx undertakes no obligation to publicly replace or revise the data on this press launch, together with any forward-looking statements, besides as could also be required by legislation.